Disease Overview：Valvular Heart Disease（VHD）
Valvular heart disease refers to structural or functional abnormalities of one or more cardiac valves—mitral, aortic, tricuspid, or pulmonary—leading to stenosis (narrowing), regurgitation (insufficiency), or prolapse. Common etiologies include degenerative changes, rheumatic fever, infective endocarditis, congenital malformations, and connective tissue disorders. Symptoms may range from asymptomatic murmurs detected on auscultation to exertional dyspnea, orthopnea, fatigue, syncope, or acute decompensated heart failure. Diagnosis relies on echocardiography (transthoracic and transesophageal), cardiac MRI, and hemodynamic assessment via right-heart catheterization when indicated. Management spans medical optimization, minimally invasive interventions—including transcatheter aortic valve replacement (TAVR), mitral clip procedures—and surgical options such as valve repair or replacement with mechanical or bioprosthetic prostheses.
China offers distinct advantages for international patients seeking valvular heart disease treatment. The country hosts nationally accredited cardiovascular centers with JCI- or CAP-accredited laboratories, equipped with next-generation imaging systems (e.g., 3D/4D echo, ultra-high-field MRI) and robotic-assisted surgical platforms. Leading institutions report >95% procedural success rates for TAVR and >90% five-year survival post-mitral valve repair—comparable to top-tier Western programs. Crucially, costs are typically 40–60% lower than in the US or Western Europe, without compromising clinical standards or regulatory oversight (NMPA-approved devices, strict adherence to ESC/AHA guidelines). As a dedicated medical tourism agency, we facilitate seamless access: vetting hospitals based on outcome metrics and international accreditation, coordinating pre-arrival diagnostics, securing priority appointments with board-certified interventional cardiologists and cardiothoracic surgeons, providing transparent all-inclusive pricing, and offering end-to-end support—from visa assistance and medical translation to postoperative rehabilitation coordination and follow-up teleconsultations.
Valvular Heart Disease: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Valvular Heart Disease (Cardiology Department)
Non-Surgical / Conservative Management
*Indicated for asymptomatic mild-moderate disease, contraindications to surgery, or preoperative stabilization.*
- •Medications (Monthly)
- Beta-blockers (e.g., metoprolol): $6–$10 - Anticoagulants (warfarin/DOACs): $25–$65 (apixaban rivaroxaban higher tier) - ACEi/ARBs (for LV dysfunction): $10–$18
- •Monitoring & Diagnostics (Per Episode)
- ECG + Holter monitoring: $20–$35 - BNP/NT-proBNP assay: $18–$28 - Renal function + INR panel: $12–$22
Surgical & Interventional Procedures
*Eligibility: Symptomatic moderate-severe stenosis/regurgitation, LVEF ≤50%, progressive ventricular dilation, or pulmonary hypertension.*
- •Transcatheter Aortic Valve Implantation (TAVI)
- Procedure (valve + cath lab + anesthesia): $18,500–$26,200 - Hospital stay (5–7 days): $1,100–$1,600
- •Surgical Aortic/ Mitral Valve Replacement (SAVR)
- Procedure (mechanical/bioprosthetic valve + CPB): $12,800–$19,400 - Hospital stay (7–10 days): $1,400–$2,100
- •Mitral Valve Repair (MVR)
- Procedure (annuloplasty, chordal reconstruction): $14,200–$20,600 - Hospital stay: $1,400–$2,100
Special/Complex Condition Management
- •Reoperative Valve Surgery (prior sternotomy, endocarditis, prosthetic failure): $17,500–$24,800 (includes extended CPB, complex tissue reconstruction)
- •Combined CABG + Valve Surgery: $21,000–$29,500
- •Endocarditis-directed therapy (IV antibiotics × 4–6 weeks + surgical debridement): $8,200–$13,600 (includes ICU days, blood cultures, valve culture)
Quick Selection Guide
- •Age <65, no comorbidities, severe AS/MR: Surgical repair/replacement — optimal durability, cost-effective long-term ($14,200–$19,400)
- •Age ≥75, frailty/COPD/renal impairment: TAVI — lower perioperative risk, faster recovery ($19,600–$27,800)
- •Asymptomatic moderate disease + tight budget: Conservative management + biannual echo ($120–$200/year)
- •Active infective endocarditis + vegetation >10 mm: Urgent surgical debridement + valve replacement — mortality reduction outweighs cost ($17,500–$24,800)
- •Severe MR with preserved EF but high surgical risk: Transcatheter edge-to-edge repair (MitraClip) — available at select 3A centers ($22,000–$28,500)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Valvular Heart Disease Medical Vacation Packages
Curated transparent all-inclusive packages combining Valvular Heart Disease treatment with China top medical destinations:
